BioMarin
BioMarin Pharmaceutical Inc., headquartered in the United States, is a leading biotechnology company specialising in innovative therapies for rare genetic diseases. Founded in 1997, BioMarin has established itself as a pioneer in the industry, focusing on the development of enzyme replacement therapies and gene therapies that address unmet medical needs.
With a strong presence in North America, Europe, and Asia, BioMarin's core products include treatments for conditions such as phenylketonuria (PKU) and mucopolysaccharidosis (MPS). The company is renowned for its commitment to research and development, which has led to several groundbreaking therapies that significantly improve patient outcomes. BioMarin's dedication to rare disease treatment has positioned it as a market leader, earning recognition for its innovative approach and impactful contributions to the biotechnology sector.
-18 vs industry average
BioMarin’s score of 20 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at BioMarin?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for BioMarin yet.
BioMarin's reported carbon emissions
BioMarin Pharmaceutical Inc., headquartered in the US, currently does not provide specific carbon emissions data for the most recent year, as indicated by the absence of reported figures. Consequently, there are no details available regarding their Scope 1, 2, or 3 emissions.
In terms of climate commitments, BioMarin has not outlined any specific reduction targets or initiatives in the provided data. This lack of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework.
As a member of the pharmaceutical industry, BioMarin is part of a sector increasingly focused on sustainability and carbon reduction. However, without specific emissions data or defined targets, it is challenging to assess their current impact or future commitments in relation to climate change.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
BioMarin’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for BioMarin yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
BioMarin
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project